Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

COVID-19: Daily Top 10 Papers

  Malignant Lymphoma

  Free Subscription


1 Am J Surg Pathol
4 Blood
1 BMC Cancer
1 BMC Neurol
1 Br J Cancer
1 Br J Dermatol
1 Br J Haematol
1 Eur J Haematol
4 Leuk Lymphoma
1 Leukemia
1 Oncogene

  Retrieve available abstracts of this week’s articles:
HTML format
Single Articles

    Am J Surg Pathol

  1. YUAN CT, Wang JT, Sheng WH, Cheng PY, et al
    Lymphadenopathy Associated With Neutralizing Anti-interferon-gamma Autoantibodies Could Have Monoclonal T-cell Proliferation Indistinguishable From Malignant Lymphoma and Treatable by Antibiotics: A Clinicopathologic Study.
    Am J Surg Pathol. 2021 May 20. pii: 00000478-900000000-97201.
    PubMed         Abstract available


  2. BISHOP DC, Clancy LE, Simms R, Burgess J, et al
    Development of CAR T-cell lymphoma in two of ten patients effectively treated with piggyBac modified CD19 CAR T-cells.
    Blood. 2021 May 19. pii: 475980. doi: 10.1182/blood.2021010813.
    PubMed         Abstract available

  3. RAASTAD K, Huang Q
    Burkitt leukemia with immature B-cell phenotype mimicking acute lymphoblastic leukemia.
    Blood. 2021;137:718.

  4. KOHLHAAS V, Blakemore SJ, Al-Maarri M, Nickel N, et al
    Active Akt signaling triggers CLL toward Richter transformation via overactivation of Notch1.
    Blood. 2021;137:646-660.
    PubMed         Abstract available

  5. DAHER M, Basar R, Gokdemir E, Baran N, et al
    Targeting a cytokine checkpoint enhances the fitness of armored cord blood CAR-NK cells.
    Blood. 2021;137:624-636.
    PubMed         Abstract available

    BMC Cancer

  6. YANG X, Khoo LP, Chang EWY, Yang VS, et al
    Treatment patterns and outcomes of older patients with mantle cell lymphoma in an Asian population.
    BMC Cancer. 2021;21:566.
    PubMed         Abstract available

    BMC Neurol

  7. DENG Y, Zhao B, Wei B, Zhang S, et al
    Parotid carcinoma following chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids: a case report.
    BMC Neurol. 2021;21:110.
    PubMed         Abstract available

    Br J Cancer

  8. CAI J, Tian X, Ma S, Zhong L, et al
    A nomogram prognostic index for risk-stratification in diffuse large B-cell lymphoma in the rituximab era: a multi-institutional cohort study.
    Br J Cancer. 2021 May 19. pii: 10.1038/s41416-021-01434.
    PubMed         Abstract available

    Br J Dermatol

  9. JONAK C, Alkon N, Rindler K, Rojahn TB, et al
    Single-cell RNAseq profiling in a patient with discordant primary cutaneous B and T cell lymphoma reveals micromilieu-driven immune skewing.
    Br J Dermatol. 2021 May 21. doi: 10.1111/bjd.20512.
    PubMed         Abstract available

    Br J Haematol

  10. GENUARDI E, Romano G, Beccuti M, Alessandria B, et al
    Application of the Euro Clonality next-generation sequencing-based marker screening approach to detect immunoglobulin heavy chain rearrangements in mantle cell lymphoma patients: first data from the Fondazione Italiana Linfomi MCL0208 trial.
    Br J Haematol. 2021 May 18. doi: 10.1111/bjh.17519.
    PubMed         Abstract available

    Eur J Haematol

  11. RENAUD L, Bossard JB, Carpentier B, Terriou L, et al
    Treatment with temozolomide and ibrutinib in Recurrent/Refractory Primary (PCNSL) and Secondary CNS Lymphoma (SCNSL).
    Eur J Haematol. 2021 May 21. doi: 10.1111/ejh.13667.
    PubMed         Abstract available

    Leuk Lymphoma

  12. PALOMBA ML, Jun MP, Lymp J, Nguyen A, et al
    Postinfusion monitoring costs by site of care for patients with relapsed/refractory large B-cell lymphoma receiving third- or later-line treatment with lisocabtagene maraleucel in the TRANSCEND NHL 001 and OUTREACH trials.
    Leuk Lymphoma. 2021 May 21:1-8. doi: 10.1080/10428194.2021.1910686.
    PubMed         Abstract available

  13. LIANG D, Wei C, Zhang X, Yang J, et al
    Efficacy of lenalidomide for relapsed or refractory T lymphoblastic lymphoma/leukemia after allogeneic hematopoietic stem cell transplantation.
    Leuk Lymphoma. 2021 May 17:1-5. doi: 10.1080/10428194.2021.1919665.

  14. WAGNER-JOHNSTON ND, Schuster SJ, deVos S, Salles G, et al
    Outcomes of patients with up to 6 years of follow-up from a phase 2 study of idelalisib for relapsed indolent lymphomas.
    Leuk Lymphoma. 2021;62:1077-1087.
    PubMed         Abstract available

  15. SEKAR A, Davids MS
    Idelalisib in indolent NHL - has it finally found its niche?
    Leuk Lymphoma. 2021;62:1029-1030.


  16. HE MY, Kridel R
    Treatment resistance in diffuse large B-cell lymphoma.
    Leukemia. 2021 May 20. pii: 10.1038/s41375-021-01285.
    PubMed         Abstract available


  17. KUNOU S, Shimada K, Takai M, Sakamoto A, et al
    Exosomes secreted from cancer-associated fibroblasts elicit anti-pyrimidine drug resistance through modulation of its transporter in malignant lymphoma.
    Oncogene. 2021 May 16. pii: 10.1038/s41388-021-01829.
    PubMed         Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Malignant Lymphoma is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.